The E2F4 Knockout HeLa Polyclonal Cells product comprises a population of HeLa cells harboring a CRISPR/Cas9-mediated disruption of the E2F4 gene. This polyclonal knockout cell pool is generated by introducing targeted gene disruptions via CRISPR/Cas9 ribonucleoproteins, resulting in a heterogeneous mixture of edited alleles. The polyclonal format preserves genetic diversity while effectively abrogating E2F4 protein expression in the majority of cells, providing a robust loss-of-function model for studying E2F4-dependent processes. This product is supplied as a ready-to-use, proliferating culture and is suitable for a variety of downstream experimental applications.
The host cell line, HeLa, is an immortalized epithelial cell line derived from a human cervical adenocarcinoma. As one of the most widely utilized cell lines in biomedical research, HeLa cells offer well-characterized growth properties, robust proliferation, and compatibility with standard cell culture protocols. Originally isolated from a cervical cancer biopsy, HeLa cells contain integrated human papillomavirus type 18 (HPV18) sequences, which lead to the expression of the viral oncoproteins E6 and E7. These oncoproteins disrupt the functions of p53 and retinoblastoma protein (RB1), respectively, creating a cellular environment with altered cell cycle and apoptotic checkpoints. This genetic background is particularly relevant for investigating the roles of E2F transcription factors and pRb pathway components in transformed epithelial cells.
E2F4 encodes a member of the E2F transcription factor family, which functions predominantly as a transcriptional repressor. Unlike activator E2Fs, E2F4 lacks a nuclear localization signal and relies on heterodimerization with TFDP1 or TFDP2 for DNA binding and nuclear import. In quiescent or differentiated cells, E2F4 forms repressive complexes with the pocket proteins RB1, RBL1 (p107), and RBL2 (p130), together with histone deacetylases (HDACs) and the corepressor SIN3A. These complexes bind to E2F promoter elements and actively silence genes required for G1/S transition and DNA replication, including CCNE1 (cyclin E), CCNA2 (cyclin A), CDC6, DHFR, TK1, and MYC. The repressor activity is regulated by cyclin-dependent kinases: CDK4/6-cyclin D and CDK2-cyclin E phosphorylate pocket proteins, leading to complex dissociation and derepression of target genes. Additionally, TGF-?? signaling reinforces E2F4-mediated repression through SMAD-dependent pathways, further linking growth inhibitory signals to cell cycle arrest.
In the HeLa context, where the RB1 pathway is already compromised by HPV E7, E2F4 retains its repressive capacity and contributes to the residual regulation of cell cycle genes. Disruption of E2F4 in this background removes a critical brake on S-phase entry, potentially leading to the derepression of its target genes and enhanced cellular proliferation. This knockout model thus serves as a powerful tool to dissect the functional interplay between viral oncogenes and host cell cycle machinery. By studying E2F4 loss in a well-characterized cervical cancer model, researchers can better understand how transcriptional repression maintains appropriate cell cycle control and how its failure contributes to tumorigenesis. Moreover, this model enables the investigation of synthetic lethal interactions or compensatory mechanisms activated upon E2F4 inactivation.
Researchers can utilize this polyclonal knockout cell population in a wide array of functional assays. Western blotting and RT-qPCR can confirm the reduction of E2F4 protein and the upregulation of target genes such as CCNE1 or CDC6. Flow cytometry-based cell cycle analysis reveals shifts in the proportion of cells in G1, S, and G2/M phases. Colony formation and MTT/BrdU proliferation assays permit quantitative assessment of growth advantage. Furthermore, this model is suited for high-throughput screening of chemical libraries to identify compounds that selectively target cells with impaired E2F4-mediated repression, supporting drug target validation in cancer. For further details or technical support, please contact Ascent Research.
